PASG Passage BIO, Inc.

Nasdaq passagebio.com


$ 8.09 $ 0.05 (0.62 %)    

Friday, 17-Oct-2025 15:59:51 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 8.07
$ 8.30
$ 7.11 x 200
$ 8.97 x 22
$ 8.00 - $ 8.55
$ 5.12 - $ 26.60
51,752
na
25.65M
$ 1.38
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-04-2025 01-01-1970 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-04-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-07-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-06-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 05-16-2022 03-31-2022 10-Q
15 03-03-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-05-2021 03-31-2021 10-Q
19 03-03-2021 12-31-2020 10-K
20 11-10-2020 09-30-2020 10-Q
21 08-13-2020 06-30-2020 10-Q
22 05-11-2020 03-31-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 canaccord-genuity-maintains-buy-on-passage-bio-lowers-price-target-to-67

Canaccord Genuity analyst Whitney Ijem maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers the price target from $260 ...

 guggenheim-maintains-buy-on-passage-bio-lowers-price-target-to-10

Guggenheim analyst Debjit Chattopadhyay maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers the price target from $40 ...

 wedbush-maintains-outperform-on-passage-bio-raises-price-target-to-40

Wedbush analyst Yun Zhong maintains Passage Bio (NASDAQ:PASG) with a Outperform and raises the price target from $3 to $40.

 passage-bio-q2-eps-296-misses-021-estimate

Passage Bio (NASDAQ:PASG) reported quarterly losses of $(2.96) per share which missed the analyst consensus estimate of $(0.21)...

 chardan-capital-maintains-buy-on-passage-bio-maintains-6-price-target

Chardan Capital analyst Geulah Livshits maintains Passage Bio (NASDAQ:PASG) with a Buy and maintains $6 price target.

 passage-bio-reports-interim-data-from-uplift-d-showing-durable-csf-pgrn-elevation-and-reduced-plasma-nfl-versus-natural-history-in-ftd-grn

PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease progressi...

 chardan-capital-maintains-buy-on-passage-bio-lowers-price-target-to-6

Chardan Capital analyst Geulah Livshits maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers the price target from $7 t...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION